These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30008894)

  • 1. Prediction and identification of human leukocyte antigen-A2-restricted cytotoxic T lymphocyte epitope peptides from the human papillomavirus 58 E7 protein.
    Wang H; Chen L; Ma W; Zeng Y; Qin L; Chen M; Li L
    Oncol Lett; 2018 Aug; 16(2):2003-2008. PubMed ID: 30008894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.
    Cheng WF; Lee CN; Su YN; Chang MC; Hsiao WC; Chen CA; Hsieh CY
    Immunology; 2005 May; 115(1):136-49. PubMed ID: 15819706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice.
    Peng S; Xing D; Ferrall L; Tsai YC; Hung CF; Wu TC
    J Biomed Sci; 2022 Oct; 29(1):80. PubMed ID: 36224625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Transformation activity and antigenicity of the human papillomavirus type 58 E6E7 fusion gene mutant].
    Wang H; Yu JY; Li L
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):491-6. PubMed ID: 24257298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine.
    Wan B; Qin L; Ma W; Wang H
    Infect Agent Cancer; 2022 Feb; 17(1):5. PubMed ID: 35197089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of antigen-epitope-specific cytotoxic T lymphocytes in patients with hepatitis B virus infection by enzyme linked immunospot assay].
    Zhang HP; Yan HP; Zhang YH; Feng X; Zhao Y; Liao HY; Liu YM; Chen Y; Tan YF; Liu Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Aug; 43(8):690-4. PubMed ID: 20021848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.
    Nilges K; Höhn H; Pilch H; Neukirch C; Freitag K; Talbot PJ; Maeurer MJ
    J Virol; 2003 May; 77(9):5464-74. PubMed ID: 12692247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preparation of HPV18 E7 peptide plus CpG vaccine and its immunologic effects in vitro].
    Liao SJ; Zhang WN; Hu XJ; Jiang XF; Wang CY; Lu YP; Wang SX; Ma D
    Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(23):1641-5. PubMed ID: 22944136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
    Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
    Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A DNA vaccine encoding mutated HPV58 mE6E7-Fc-GPI fusion antigen and GM-CSF and B7.1.
    Wang H; Yu J; Li L
    Onco Targets Ther; 2015; 8():3067-77. PubMed ID: 26604780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
    Street MD; Doan T; Herd KA; Tindle RW
    Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes.
    van der Burg SH; Ressing ME; Kwappenberg KM; de Jong A; Straathof K; de Jong J; Geluk A; van Meijgaarden KE; Franken KL; Ottenhoff TH; Fleuren GJ; Kenter G; Melief CJ; Offringa R
    Int J Cancer; 2001 Mar; 91(5):612-8. PubMed ID: 11267969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.
    Liu DW; Yang YC; Lin HF; Lin MF; Cheng YW; Chu CC; Tsao YP; Chen SL
    J Virol; 2007 Mar; 81(6):2869-79. PubMed ID: 17202211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
    Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T
    Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
    Smyth LJ; Van Poelgeest MI; Davidson EJ; Kwappenberg KM; Burt D; Sehr P; Pawlita M; Man S; Hickling JK; Fiander AN; Tristram A; Kitchener HC; Offringa R; Stern PL; Van Der Burg SH
    Clin Cancer Res; 2004 May; 10(9):2954-61. PubMed ID: 15131030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel immunogenic human leukocyte antigen-A 2402-binding epitopes of human papillomavirus type 16 E7 for immunotherapy against human cervical cancer.
    Jang S; Kim YT; Chung HW; Lee KR; Lim JB; Lee K
    Cancer; 2012 Apr; 118(8):2173-83. PubMed ID: 21918960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line.
    Youde SJ; McCarthy CM; Thomas KJ; Smith KL; Man S
    Int J Cancer; 2005 Apr; 114(4):606-12. PubMed ID: 15609329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope.
    Alexander M; Salgaller ML; Celis E; Sette A; Barnes WA; Rosenberg SA; Steller MA
    Am J Obstet Gynecol; 1996 Dec; 175(6):1586-93. PubMed ID: 8987945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented.
    Bauer M; Wagner H; Lipford GB
    Immunol Lett; 2000 Jan; 71(1):55-9. PubMed ID: 10709786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.